CLVS - クロビス・オンコロジ― (Clovis Oncology Inc.) クロビス・オンコロジ―

 CLVSのチャート


 CLVSの企業情報

symbol CLVS
会社名 Clovis Oncology Inc (クロビス・オンコロジ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 クロービス・オンコロジー(Clovis Oncology Inc.)は米国、ヨーロッパ及び他の国際市場における抗癌剤の取得・開発・商品化に従事するバイオ医薬品会社である。同社の製品候補にはロシリチニブ、ルブラカ(ルカパリブ)及びルシチニブを含む。ルカパリブは損傷デオキシリボ核酸乳癌(DNA)の修復関連ヒト遺伝子の乳がん(BRCA)突然変異患者の治療向け単剤療法として承認されたPARP1、PARP2及びPARP3の経口小分子ポリアデノシン二リン酸(ADP)・リボースポリメラーゼ(PARP)阻害剤である。ルシチニブは、血管内皮増殖因子受容体(VEGFR)1-3、血小板由来増殖因子受容体(PDGFR)αとβ及び線維芽細胞増殖因子受容体(FGFR)1-3のチロシンキナーゼ活性の経口阻害剤である。ロシリチニブは表皮成長因子受容体(EGFR)の経口突然変異選択的阻害剤である。   クロビス・オンコロジ―は米国のバイオ医薬品会社。抗がん剤の買収、開発、商業化を手掛ける。非小細胞肺がん治療用に経口の選択的・非可逆的EGFR阻害剤CO-186を、また、卵巣がんおよびすい臓がん治療用にポリ(ADP-リボ―ス)ポリメラ―ゼ阻害剤ルカパリブの臨床開発を実施している。   Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
本社所在地 5500 Flatiron Parkway Suite 100 Boulder CO 80301 USA
代表者氏名 M. James E. Barrett M.ジェームスE.バレット
代表者役職名 Independent Chairman of the Board
電話番号 +1 303-625-5000
設立年月日 39904
市場名 NASDAQ National Market System
ipoyear 2011年
従業員数 360人
url www.clovisoncology.com
nasdaq_url https://www.nasdaq.com/symbol/clvs
adr_tso
EBITDA EBITDA(百万ドル) -268.68600
終値(lastsale) 30.34
時価総額(marketcap) 1597388590.94
時価総額 時価総額(百万ドル) 1531.05
売上高 売上高(百万ドル) 76.12600
企業価値(EV) 企業価値(EV)(百万ドル) 1423.143
当期純利益 当期純利益(百万ドル) -129.23100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Clovis Oncology Inc revenues increased 95% to $42.3M. Net loss decreased 24% to $178.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Legal settlement loss decrease of 93% to $8M (expense) Other income increase from $948K to $2.9M (income).

 CLVSのテクニカル分析


 CLVSのニュース

   Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020  2020/06/17 12:00:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
   Why Is Clovis (CLVS) Down 17.2% Since Last Earnings Report?  2020/06/04 15:31:22 Zacks Investment Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)  2020/05/28 12:00:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the National Comprehensive Cancer Network® (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to include new recommendations for Rubraca® (rucaparib) tablets.i In addition to its ovarian cancer recommendations, Rubraca is now recommended in the NCCN Guidelines® for the treatment of BRCA-mutant patients with mCRPC under second-line treatment and subsequent therapy as a Categor
   Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program  2020/05/21 20:10:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
   Clovis launches $85M stock offering on heels of FDA approval  2020/05/19 01:29:39 Daily Camera
Days after it landed approval to use its flagship drug to treat pancreatic cancer, Clovis Oncology Inc. said it intends to sell $85 million in new stock.
   Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates  2020/05/06 15:17:00 Zacks Investment Research
Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.
   Clovis Oncology Announces First Quarter 2020 Operating Results  2020/05/05 20:05:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2020, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for the rest of the year. “We are pleased with our sales growth in the first quarter and believe that Rubraca is well-positioned as an oncology treatment option in the COVID-19 era,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “While we m
   Clovis Oncology to Present at the Bank of America Health Care Conference 2020  2020/04/29 20:05:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America Health Care Conference 2020 on Tuesday, May 12, 2020 at 10:20 a.m. Eastern time. This conference is virtual and a live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcas
   Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?  2020/04/22 13:00:00 Zacks Investment Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
   Clovis Oncology Announces Debt Exchange Transaction  2020/04/14 21:08:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on April 14, 2020 it entered into a privately negotiated exchange agreement with a holder of its 2.50% Convertible Senior Notes due 2021 (the “2021 Notes”). Pursuant to the exchange agreement, Clovis Oncology will issue to such holder of the 2021 Notes approximately $36.05 million in aggregate principal amount of its currently outstanding series of 4.50% Convertible Senior Notes due 2024 (the “2024 Notes”
   Why Is Clovis (CLVS) Down 41.6% Since Last Earnings Report?  2020/03/25 15:30:23 Zacks Investment Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat  2020/02/25 09:12:00 Zacks Investment Research
Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues. Shares down.
   Clovis Oncology (NASDAQ: CLVS): Q4 2019 Earnings Snapshot  2020/02/24 21:13:28 news.alphastreet.com
— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected. — Product revenues…
   Clovis Oncology Announces 2019 Operating Results  2020/02/24 21:05:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces 2019 Operating Results
   Is Clovis Oncology (CLVS) Outperforming Other Medical Stocks This Year?  2020/02/21 16:30:10 Zacks Investment Research
Is (CLVS) Outperforming Other Medical Stocks This Year?

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クロビス・オンコロジ― CLVS Clovis Oncology Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)